Chemistry:LY-344545
From HandWiki
Short description: Chemical compound
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C20H19NO5 |
Molar mass | 353.374 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
LY-344,545 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as an antagonist for the metabotropic glutamate receptor subtype mGluR5. It is an epimer of another metabotropic glutamate receptor antagonist, the mGluR2/3-selective LY-341,495.[1][2]
References
- ↑ "2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability". Journal of Medicinal Chemistry 41 (3): 358–78. January 1998. doi:10.1021/jm970498o. PMID 9464367.
- ↑ "A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices". British Journal of Pharmacology 131 (2): 239–44. September 2000. doi:10.1038/sj.bjp.0703574. PMID 10991916.
Original source: https://en.wikipedia.org/wiki/LY-344545.
Read more |